The disposition and metabolism of captopril

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Medicinal research reviews (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/med.2610060104PMID 3005787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Captopril: An Update Review of its Pharmacological Properties and Therapeutic Efficacy in Congestive Heart Failure

  2012cited by this paper
• Effect of probenecid on the disposition of captopril and captopril dimer in the rat.

  1985cited by this paper
• CAPTOPRIL DURING PREGNANCY

  1984cited by this paper
• Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.

  1984cited by this paper
• EFFECT OF CAPTOPRIL ON BRAIN CONVERTING ENZYME IN THE SPONTANEOUSLY HYPERTENSIVE RAT

  1984cited by this paper
• Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation.

  1984cited by this paper
• Quantitative determination of captopril in blood and captopril and its disulfide metabolites in plasma by gas chromatography.

  1984cited by this paper
• Captopril during pregnancy.

  1984cited by this paper
• Spectrofluorometric determination of captopril plus captopril disulfide metabolites in plasma.

  1984cited by this paper
• Captopril: pharmacology, metabolism and disposition.

  1984cited by this paper
• Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

  1984cited by this paper
• Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat.

  1984cited by this paper
• Combined gas chromatographic-mass spectrometric procedure for the measurement of captopril and sulfur-conjugated metabolites of captopril in plasma and urine.

  1984cited by this paper
• Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions.

  1984cited by this paper
• Identification and determination of the S-methyl metabolite of captopril in human plasma by selected-ion monitoring gas chromatography-mass spectrometry.

  1984cited by this paper
• Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid.

  1984cited by this paper
• A radioimmunoassay for total captopril in human serum or plasma samples.

  1984cited by this paper
• Determination of total captopril in human plasma by gas chromatography-mass spectrometry with selected-ion monitoring after reduction of disulfides.

  1984cited by this paper
• S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues.

  1983cited by this paper
• Systemic and regional haemodynamic effects of renal denervation in spontaneously hypertensive rats.

  1983cited by this paper
• Metabolism of captopril-L-cysteine, a captopril metabolite, in rats and dogs.

  1983cited by this paper
• Effect of acute oral administration of captopril and MK-421 on vascular angiotensin converting enzyme activity in the spontaneously hypertensive rat.

  1983cited by this paper
• Captopril and MK-421: stability on storage, distribution to the central nervous system, and onset of activity.

  1983cited by this paper
• Development and pharmacology of angiotensin converting enzyme inhibitors.

  1983cited by this paper
• Drug-protein conjugates--IV. The effect of acute renal failure on the disposition of [14C]captopril in the rat.

  1983cited by this paper
• Development and optimisation of a radioimmunoassay for plasma captopril.

  1983cited by this paper
• Drug protein conjugates--VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates.

  1983cited by this paper
• Tissue distribution of captopril, reducible captopril conjugates and S-methylcaptopril in the rat.

  1983cited by this paper
• Dissociation between in vivo and in vitro measurements of converting enzyme activity after chronic oral treatment with captopril in rats.

  1982cited by this paper
• Determination of captopril and its disulphide in biological fluids.

  1982cited by this paper
• Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency.

  1982cited by this paper
• Effect of Food on the Bioavailability of Captopril in Healthy Subjects

  1982cited by this paper
• Sequential electrochemical reduction, solvent partition, and automated thiol colorimetry for urinary captopril and its disulfides.

  1982cited by this paper
• Captopril kinetics

  1982cited by this paper
• Renal handling of captopril: Effect of probenecid

  1982cited by this paper
• Inhibition of canine lung angiotensin converting enzyme by ACTH and structurally related peptides.

  1982cited by this paper
• Determination of captopril in human blood and urine by GLC-selected ion monitoring mass spectrometry after oral coadministration with its isotopomer.

  1982cited by this paper
• Biotransformation of the disulfide of captopril in subcellular fractions of rat tissues.

  1982cited by this paper
• Determination of captopril in human blood by high-performance liquid chromatography with electrochemical detection.

  1982cited by this paper
• Distribution of captopril to foetuses and milk of rats.

  1982cited by this paper
• Drug protein conjugates--I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat.

  1982cited by this paper
• Captopril kinetics in chronic congestive heart failure

  1982cited by this paper
• Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421.

  1982cited by this paper
• Pharmacokinetic properties of captopril after acute and chronic administration to hypertensive subjects.

  1982cited by this paper
• Hypertensive mechanisms : the spontaneously hypertensive rat as a model to study human hypertension

  1982cited by this paper
• The Determination of Captopril in Physiological Fluids Using High Perf Ormance Liquid Chromatography With Electrochemical Detection

  1982cited by this paper
• A Peptide Inhibitor of Angiotensin I Converting Enzyme in the Tryptic Hydrolysate of Casein

  1982cited by this paper
• Determination of captopril in blood and urine by high-performance liquid chromatography.

  1981cited by this paper
• Pharmacokinetics of captopril in dogs and monkeys.

  1981cited by this paper
• A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin.

  1981cited by this paper
• In vitro studies on the metabolic pathway of SQ 14225 (Captopril) and mechanism of mixed disulfide formation.

  1981cited by this paper
• Inhibition of angiotensin converting enzyme of rat brain with bradykinin and its fragments.

  1981cited by this paper
• Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet.

  1981cited by this paper
• High-performance liquid chromatographic analysis of captopril in plasma.

  1981cited by this paper
• Active-Site Specific Inhibitors of Angiotensin-Converting Enzyme

  1981cited by this paper
• Captopril in Human Blood and Breast Milk

  1981cited by this paper
• Blood Concentration and Urinary Excretion of Captopril (SQ 14,225) in Patients with Chronic Renal Failure

  1981cited by this paper
• In vitro biotransformations of [14C]captopril in the blood of rats, dogs and humans.

  1981cited by this paper
• Gas chromatography/selected ion monitoring mass spectrometric determination of captopril in human blood.

  1980cited by this paper
• A new class of angiotensin-converting enzyme inhibitors

  1980cited by this paper
• Disposition of captopril in normal subjects

  1980cited by this paper
• Effects of captopril in animal models of hypertension.

  1980cited by this paper
• Determination of captopril in biological fluids by gas-liquid chromatography.

  1980cited by this paper
• Determinatin of captopril in biological fluids by gas-liquid chromatography

  1980cited by this paper
• Captopril: A Preliminary Review of its Pharmacological Properties and Therapeutic Efficacy

  1980cited by this paper
• Decarboxylated S-adenosylmethionine in mammalian cells.

  1980cited by this paper
• A thin-layer chromatographic method for the quantitative separation and estimation of S-adenosylmethionine and S-adenosylethionine in rat liver.

  1980cited by this paper
• Excretion of 3 Methylhistidine to Measure Human-Muscle Protein-Turnover

  1980cited by this paper
• Thin-Layer Radiochromatographic Determination of Captopril (SQ 14,225) and its Disulfide Dimer Metabolite in Blood

  1980cited by this paper
• Human erythrocyte thiol methyltransferase: radiochemical microassay and biochemical properties.

  1979cited by this paper
• Captopril (SQ 14,225) (D-3-mercapto-2-methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent.

  1978cited by this paper
• Influence of endogenous S-adenosylmethionine on the determination of catechol O-methyltransferase activity in red blood cells.

  1978cited by this paper
• Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.

  1978cited by this paper
• Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

  1977cited by this paper
• Blood-Brain Barrier in Physiology and Medicine

  1976cited by this paper
• Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis.

  1971cited by this paper
• Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom.

  1970cited by this paper
• RENAL TUBULAR MECHANISMS FOR EXCRETION OF ORGANIC ACIDS AND BASES.

  1964cited by this paper

• Exploring the multiple effects of nifedipine and captopril administration in spontaneously hypertensive rats through pharmacokinetic‐pharmacodynamic analyses

  2024cites this paper
• Clonidine versus Captopril for Severe Postpartum Hypertension: A Randomized Controlled Trial

  2017cites this paper
• Clonidine versus captopril for treatment of postpartum very high blood pressure: study protocol for a randomized controlled trial (CLONCAP)

  2013cites this paper
• Idiosyncratic reactions and metabolism of sulfur-containing drugs

  2012cites this paper
• Captopril and its dimer captopril disulfide: photodegradation, aerobic biodegradation and identification of transformation products by HPLC-UV and LC-ion trap-MS(n).

  2012cites this paper
• Diverse approaches for the enhancement of oral drug bioavailability

  2011cites this paper
• Improving the oral bioavailability of drugs through the design of modeled pre-systemic cytochrome P450 inhibitors

  2010influential citation
• Drug dosing in chronic kidney disease.

  2005cites this paper
• The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: Comparison with patients with normal renal function

  2004cites this paper
• ACE Inhibitors: Pharmacology

  2004cites this paper
• Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.

  1998cites this paper
• Peut-on substituer un inhibiteur de l'enzyme de conversion à un autre?

  1996cites this paper
• Converting enzyme inhibitors in cardiovascular therapy: current status and future potential.

  1994cites this paper
• Captopril does not protect against renal oxidative injury.

  1992cites this paper
• Angiotensin Converting Enzyme Inhibition in Heart, Kidney, and Serum Studied Ex Vivo after Administration of Zofenopril, Captopril, and Lisinopril

  1991cites this paper
• Voltammetry of captopril on the hanging mercury drop electrode

  1991cites this paper
• Disposition and metabolism of the angiotensin-converting enzyme inhibitor [4S-[4 alpha, 7 alpha, (R*), 12b beta]]-7-[S-(1-ethoxycarbonyl-3- phenylpropyl)amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo- pyrido[2,1-a][2]benzazepine-4-carboxylic acid in monkeys and dogs.

  1991cites this paper
• [Relations between pharmacokinetics and effectiveness of ACE inhibitors].

  1991cites this paper
• Captopril pharmacokinetics, blood pressure response and plasma renin activity in normotensive children with renal scarring.

  1991cites this paper
• Saturable Pharmacokinetics in the Renal Excretion of Drugs

  1989cites this paper
• RECENT ADVANCES IN PHARMACEUTICAL CHEMISTRY—ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS

  1989influential citation
• Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.

  1989cites this paper
• Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases

  1988cites this paper
• Bradykinin-potentiating activity of captopril disulphide dimer (SQ 14,551).

  1988cites this paper
• Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

  1988cites this paper
• Biotransformation studies of di-acid angiotensin converting enzyme inhibitors.

  1988cites this paper
• Biotransformation studies of di-acid angiotensin converting enzyme inhibitors.

  1987cites this paper
• THERAPEUTIC PROGRESS–REVIEW XXIX IS THERE A ROLE FOR LOW‐DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION?

  1987cites this paper